XML 39 R29.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration Agreements - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) $ in Thousands | Mar. 31, 2018 USD ($)
--- | ---
Astellas Agreement [Member] | Japan [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | $ 71,723
Deferred Revenue | 436
Total Consideration | 72,159
Astellas Agreement [Member] | Japan [Member] | License [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 59,766
Deferred Revenue | 0
Total Consideration | 59,766
Astellas Agreement [Member] | Japan [Member] | Manufacturing-clinical supplies [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 11,957
Deferred Revenue | 436
Total Consideration | 12,393
Astellas Agreement [Member] | Europe [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 559,537
Deferred Revenue | 6,101
Total Consideration | 565,638
Astellas Agreement [Member] | Europe [Member] | License [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 370,481
Deferred Revenue | 0
Total Consideration | 370,481
Astellas Agreement [Member] | Europe [Member] | Manufacturing-clinical supplies [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 189,056
Deferred Revenue | 6,101
Total Consideration | 195,157
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 616,607
Deferred Revenue | 148,369
Total Consideration | 764,976
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 286,216
Deferred Revenue | 0
Total Consideration | 286,216
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 330,391
Deferred Revenue | 36,360
Total Consideration | 366,751
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member] |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] |
Cumulative Revenue | 0
Deferred Revenue | 112,009
Total Consideration | $ 112,009

X
- Definition The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition. + References No definition available. + Details
Name: | fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date. + References No definition available. + Details
Name: | fgen_CumulativeRevenueLicenseAndDevelopmentRevenueRecognized
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_ManufacturingClinicalSuppliesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=fgen_UnitedStatesRestOfWorldAndChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=fgen_ChinaPerformamceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |